| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
M-443 manufacturers
- M443
-
- $132.00
-
2026-07-27
- CAS:1820684-31-8
- Purity: 98.95%
- Supply Ability: 10g
|
| Product Name: | M-443 | | Synonyms: | M-443;M-443
(M443;Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-[1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-2-pyrimidinyl]amino]-;M443, 10 mM in DMSO | | CAS: | 1820684-31-8 | | MF: | C31H30F3N7O2 | | MW: | 589.61 | | EINECS: | | | Product Categories: | | | Mol File: | 1820684-31-8.mol |  |
| | M-443 Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 55 mg/mL (93.28 mM) | | form | Solid | | pka | 12.95±0.70(Predicted) | | color | Light yellow to yellow |
| | M-443 Usage And Synthesis |
| Description | M443 is a specific small molecule inhibitor of MRK. M443 strongly radiosensitizes UW228 medulloblastoma cells as well as UI226 patient-derived primary cells, whereas it does not affect the response to radiation of normal brain cells. M443 also inhibits radiation-induced activation of both p38 and Chk2, two proteins that act downstream of MRK and are involved in DNA damage-induced cell-cycle arrest. | | Uses | M443 is an irreversible and specific inhibitor of MRK, with an IC50<125 nM. | | in vivo | Control mice survive with a median of 32 days after tumor cell implantation. Treatment with M443 alone adds 5.5 days to this survival, whereas the chosen low dose of radiation does not significantly increase survival. In contrast, the combination of M443 and IR extend survival with a median of 16 days longer than control. Treatment with M443 does not affect the animal weight, as the weight loss observed is observed in all groups just a few days before the animals became moribund. It is showed that the tumor-containing fraction has elevated levels of both total and active MRK (lane RB in the vehicle-treated brain). In contrast, the tumor-containing fraction from the M443-treated brain shows total loss of MRK activity. Interestingly, the fractions containing normal brain, which in the control brain show some level of MRK protein, in the treated brain also has lost MRK, suggesting that diffusion of M443 across the whole cerebellum inhibit normal MRK as well[1]. | | References | [1] Markowitz D, et al. Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma. Mol Cancer Ther. 2016 Aug;15(8):1799-808. DOI:10.1158/1535-7163.MCT-15-0849 |
| | M-443 Preparation Products And Raw materials |
|